SEATTLE, July 30, 2021, (MEDGADGET) — The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Analysis
Overview
Thrombocytopenia is a blood condition in which a patient’s platelet count is abnormally low. Inefficient platelet accumulation, platelet acceleration, and platelet splenic sequestration are the main causes of thrombocytopenia. Thrombocytopenia may be hereditary or acquired, with bone marrow deficiency syndromes such as aplastic anemia and myelodysplastic syndrome among the most prevalent causes of inadequate thrombocyte development. As per a research report titled ‘Frequency of Thrombocytopenia’ published in 2014, the frequency of thrombocytopenia is greater in people aged 60 and over who have non-cirrhotic liver disease. However, the rapid development of thrombopoietin, along with the potential to clone it, has resulted in novel therapeutic options for clinical manifestations.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/3171
The demand for the Middle East and Turkey immune thrombocytopenic purpura (ITP) treatment drugs market was estimated at US$ 82.23 million in 2019 and is projected to develop at a CAGR of 4.0 percent from 2019 to 2027.
Drivers
The demand is projected to expand due to the increased launch of new products by major players in the Middle East and Turkey immune thrombocytopenic purpura (ITP) treatment drugs market. The priority of key actors is on new drug discovery and development to meet the unmet needs of patients with ITP disease. Dova Pharmaceuticals, Inc. obtained FDA clearance in June 2019 for a sNDA (supplementary New Drug Application) to extend the use of the DOPTELET (avatrombopag) drug for persistent immune thrombocytopenia (ITP) in adults who had a poor reaction to previous therapy. DOPTELET is scheduled to be published in the Asia Pacific, the Middle East, and Africa in 2021 by Dova Pharmaceuticals, Inc.
Over the forecast period, the Middle East and Turkey immune thrombocytopenic purpura (ITP) Treatment Drugs market is expected to expand due to increased healthcare infrastructure and investment in the construction of better medical facilities. SSMC (Sheikh Shakhbout Medical City), one of the ten biggest hospitals in the United Arab Emirates, began a 3.2-million-square-foot expansion in November 2019. Residents in Abu Dhabi will benefit from better access to healthcare thanks to the new hospital. The hospital is the first of its kind in the UAE, offering specialized treatment treatments as well as specialist medical programs including orthopedic and thoracic surgery.
“Limited Time Offer”
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3171
Restraints
Due to the great performance, complementary surgical treatments such as splenectomy and bone marrow transplants are often used to treat ITP. Over the forecast period, these factors are likely to restrain the development of the Middle East and Turkey immune thrombocytopenic purpura (ITP) Treatment Drugs market. Splenectomy cures ITP by destroying both the main site of platelet degradation and a significant site of antiplatelet antibody formation in a substantial proportion of patients, according to evidence released in the Al-Aqsa University Journal in January 2017. Laparoscopic splenectomy has a success rate of 72 percent after 5 years, according to the same article.
Regional Insights
Due to strategic alliances by key players in order to sell their goods across the world, Turkey is expected to maintain a leading role in the Middle East and Turkey immune thrombocytopenic purpura (ITP) Treatment Drugs market, which is aiding the growth of the Turkey immune thrombocytopenia purpura market. In January 2019, Rigel Pharmaceuticals, Inc. partnered with Grifols S.A. of Spain to commercialize fostamatinib disodium hexahydrate in all future indications in Europe and Turkey.
In the Middle East and Turkey, the demand for immune thrombocytopenic purpura (ITP) treatment drugs is expected to expand rapidly. Over the forecast period, Saudi Arabia is predicted to gain traction due to an increase in the prevalence of immune thrombocytopenia purpura among the country’s pediatric population. About 86 percent of pediatric cases of ITP are under the age of six, according to a study report released in December 2014 by Saudi Arabia’s King Khalid University. According to the same report, females account for 58 percent of pediatric patients.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/middle-east-and-turkey-immune-thrombocytopenic-purpura-treatment-drugs-market-2572
Competitive Landscape
Major companies contributing to the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market are Novartis AG, Octapharma AG, Amgen Inc., Rigel Pharmaceuticals, Inc., and Swedish Orphan Biovitrum AB.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Regulatory Landscape
- Reimbursement Scenario
- PEST Analysis
- Epidemiology Analysis
- Diagnosis Rate/Ratio
- Patient and Physician Perspective About the Existing Treatment
- Market Dynamics
- The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Drug Type, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Steroid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Thrombopoietin Receptor Agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- The Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Country, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Country, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Country, 2017 – 2027
- Country Trends
- Turkey
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Israel
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Egypt
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Saudi Arabia
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- UAE
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Rest of the Middle East
- Market Size and Forecast, By Drug Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
- Competitive Landscape
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
Other Exclusive Reports:
Central Nervous System Disorders Therapeutics Market To Surpass US$ 202.7 Million By 2028
Diabetic Foot Ulcer Treatment Market To Surpass US$ 12,653.3 Million By 2028
Anti-Epileptic Drugs Market To Surpass US$ 7,344.9 Million By 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837